L01EX01 • sunitinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Sunitinib is a tyrosine kinase inhibitor used in the treatment of certain types of cancer, such as renal cell carcinoma and gastrointestinal stromal tumors. It works by blocking receptors involved in the growth and spread of tumor cells.
The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and undergo regular medical check-ups to monitor the response to treatment.
Patients should be aware of potential side effects, such as fatigue, nausea, or high blood pressure. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, nausea, diarrhea, and changes in blood pressure. In rare cases, severe reactions such as heart failure or tumor lysis syndrome may occur. Patients should be informed of these risks before starting treatment.
Substance: sunitinib
Date of last drug list: 01-08-2019
Commercial code: W65987003
Concentration: 12.5mg
Pharmaceutical form: capsules
Quantity: 30
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: REMEDICA LTD. - CIPRU
Holder: ALVOGEN MALTA OPERATIONS (ROW) LTD. - MALTA
Number: 11702/2019/03
Shelf life: 2 years